Rexahn Pharmaceuticals Receives Positive Opinion from European Medicines Agency for Orphan Drug Designation for RX-3117

Oct 10, 2017

Rexahn Pharmaceuticals to Present at the 2017 Disruptive Growth Company Showcase NYC

Sep 21, 2017

Rexahn Pharmaceuticals Presents Final Data from the Supinoxin™ Phase I Clinical study and New Preclinical Data on RX-3117 at the 2017 European Society for Medical Oncology (ESMO) Congress

Sep 11, 2017

Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Advanced Bladder Cancer at the 2017 European Society for Medical Oncology (ESMO) Congress

Sep 10, 2017

Rexahn Pharmaceuticals to Present at 19th Annual Rodman & Renshaw Global Investment Conference

Sep 6, 2017

Rexahn Pharmaceuticals to Present Updated Clinical and Preclinical Data at the 2017 European Society for Medical Oncology (ESMO) Congress

Sep 5, 2017

Rexahn Pharmaceuticals Announces Retirement of its Founder, Chang Ahn, Ph.D., from the Board of Directors

Sep 1, 2017

Rexahn Pharmaceuticals Receives New U.S. Patent for Supinoxin™

Aug 30, 2017

Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans

Aug 14, 2017

Rexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results

Aug 7, 2017